Health ❯ Healthcare ❯ Obesity

Treatment Options

Semaglutide Oral Medications GLP-1 Medications GLP-1 Drugs Weight Loss Injections GLP-1 Agonists Injectable Medications Medication Pharmaceuticals Orforglipron

Medicare Opens $50 GLP-1 Bridge as Doctors Warn of Patient Surge

The temporary drug program could flood clinics and expose gaps in monitoring, prior authorization and patient support.

MHRA Approves Wegovy Daily Pill for Weight Loss in UK

UAE Becomes First Country Outside U.S. to Offer Wegovy Pill

Study Links GLP‑1 Drugs to Fewer Knee Replacements in People With Osteoarthritis

EMS’s Ozivy Cleared by Anvisa as First Synthetic Semaglutide Pen After Patent Expiry

France to Reimburse Wegovy and Mounjaro Under Strict Rules

Novo Nordisk Narrows Gap With Lilly as Wegovy Pill Leads Early Oral Sales

Oral GLP‑1 Approval and New Trials Push Weight‑Loss Drugs Into Mass Market

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

French Drug Regulator Fines Novo Nordisk and Eli Lilly Over Obesity Drug Promotions

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Genetic Clues Help Explain GLP‑1 Differences in Results

UK Regulators Approve Single-Dose 7.2mg Wegovy Pen for Weekly Use

France’s Weight-Loss Drug Boom Spurs Shortages, Safety Alerts, and a Shadow Market

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

Emcure Slashes Price of Novo’s Semaglutide Brand Poviztra by Up to 55% in India

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs